|
WO2021072330A1
|
|
Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
|
|
WO2021072203A1
|
|
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
|
WO2021067644A1
|
|
Combination therapy with immune stimulatory conjugates
|
|
WO2021030665A1
|
|
Formulations of benzazepine conjugates and uses thereof
|
|
WO2021011834A1
|
|
Alk5 inhibitors, conjugates, and uses thereof
|
|
WO2020257407A1
|
|
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
WO2020181040A1
|
|
Cyclic amino-pyrazinecarboxamide compounds and uses thereof
|
|
WO2020056194A1
|
|
Benzazepine compounds, conjugates, and uses thereof
|
|
WO2020056198A2
|
|
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
AU2019337652A1
|
|
Antibody conjugates of toll-like receptor agonists
|
|
AU2019339344A1
|
|
Compositions for the treatment of disease with immune stimulatory conjugates
|
|
KR20210023837A
|
|
Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
|
|
WO2019195278A1
|
|
Alk5 inhibitors, conjugates, and uses thereof
|
|
AU2018385693A1
|
|
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
WO2019084060A1
|
|
Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
|
|
WO2019079357A1
|
|
Tnik modulators, conjugates, and uses thereof
|
|
WO2018227023A1
|
|
Antibody construct conjugates
|
|
AU2018279105A1
|
|
Antibody conjugates of immune-modulatory compounds and uses thereof
|
|
MX2019010804A
|
|
Benzazepine compounds, conjugates, and uses thereof.
|
|
US2020199242A1
|
|
Construct-peptide compositions and methods of use thereof
|
